Needham Comments On Medarex (MEDX) After Encouraging Mayo Clinic Cancer News
More News related to MEDX
- GENova appoints Dr. Philip Gould to Scientific Advisory Board
- Bristol-Myers Squibb (BMY) Completes Acquisition of Medarex
- Bristol-Myers Squibb (BMY) Completes Tender Offer for Medarex (MEDX)
- Notable Mergers and Acquisitions of the Day 8/21: MNOV/AVGN, BMY/MEDX, ORCL/JAVA
- Bristol-Myers (BMY) Extends Tender Offer for Medarex (MEDX) to August 26
More News related to Analyst Comments
- Moody's Suggests AIG (AIG) Could Repay the U.S.
- Enterprise Tech Rebound Is Real - Analyst (HPQ, NTAP, STX, ARW)
- Credit Suisse Boosts Price Target on HP (HPQ) to $60
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Goldman Sachs Adds Smith & Nephew (SNN) To Their Conviction Buy List
Analysts at Needham & Co commented on Medarex, Inc. (Nasdaq: MEDX) related to encouraging news that an ongoing Mayo Clinic Phase 2 study on the use of ipilimumab in advanced prostate cancer in combination therapy with androgen ablation.
The firm said, "We think the data today are suggestive of activity for ipilimumab in this cancer and its potential as a "pipeline within a drug," as ipilimumab is being tested across multiple cancers including melanoma (Phase 3) and NSCLC (Phase 2). Yet we still believe that the Phase 3 melanoma trial with data expected 1H10 is the main value driver of the stock at this time."
The firm is maintaining their Buy rating and $11 price target.
Shares of Medarex are up 16% today on the back of the Mayo Clinic news.
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
